Agilent Technologies Licenses Kreatech Technology, Enabling First CGH Microarrays Optimized for FFPE Samples

Agilent Technologies Inc. (NYSE: A) and Kreatech Biotechnology B.V. announced today that Agilent has licensed novel labeling technology from Kreatech, which will optimize Agilent’s array-based comparative genomic hybridization (aCGH) platform for DNA from formalin-fixed paraffin-embedded (FFPE) tissue samples.

Source: Agilent Technologies